Paradigm Biopharmaceuticals is a commercially-focused drug development company that is dedicated to transforming underutilized molecules. They believe that this approach is the most optimal path to address unmet needs in medicine. Paradigm's main focus is on developing effective and safe treatments for targeted clinical indications where there are limited options available to patients.

Currently, they are concentrating their efforts on injectable pentosan polysulfate sodium (iPPS/PPS), under the brand name Zilosul®, for the treatment of osteoarthritis (OA). This is a global unmet need, and Paradigm has advanced to phase 3 trials. By addressing inflammation, pain, and regeneration, their product has the potential to genuinely modify the disease.

With headquarters in Melbourne, Australia, Paradigm also has offices in the EU and US. They are always seeking people and partners who share their vision of transforming medicines and improving patients' lives